Automated and Visual Scoring Methods of Cerebral White Matter Hyperintensities: Relation with Age and Cognitive FunctionTiehuis A.M.a · Vincken K.L.b · Mali W.P.T.M.a · Kappelle L.J.c · Anbeek P.b · Algra A.c, d · Biessels G.J.c
aDepartment of Radiology, bImage Sciences Institute, cRudolf Magnus Institute of Neuroscience, Department of Neurology, and dJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background and Purpose: A reliable scoring method for ischemic cerebral white matter hyperintensities (WMH) will help to clarify the causes and consequences of these brain lesions. We compared an automated and two visual WMH scoring methods in their relations with age and cognitive function. Methods: MRI of the brain was performed on 154 participants of the Utrecht Diabetic Encephalopathy Study. WMH volumes were obtained with an automated segmentation method. Visual rating of deep and periventricular WMH (DWMH and PWMH) was performed with the Scheltens scale and the Rotterdam Scan Study (RSS) scale, respectively. Cognition was assessed with a battery of 11 tests. Results: Within the whole study group, the association with age was most evident for the automated measured WMH volume (β = 0.43, 95% CI = 0.29–0.57). With regard to cognition, automated measured WMH volume and Scheltens DWMH were significantly associated with information processing speed (β = –0.22, 95% CI = –0.40 to –0.06; β = –0.26, 95% CI = –0.42 to –0.10), whereas RSS PWMH were associated with attention and executive function (β = –0.19, 95% CI = –0.36 to –0.02). Conclusion: Measurements of WMH with an automated quantitative segmentation method are comparable with visual rating scales and highly suitable for use in future studies to assess the relationship between WMH and subtle impairments in cognitive function.
© 2007 S. Karger AG, Basel
- de Groot JC, de Leeuw FE, Oudkerk M, et al: Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000;47:145–151.
- Ovbiagele B, Saver JL: Cerebral white matter hyperintensities on MRI: current concepts and therapeutic implications. Cerebrovasc Dis 2006;22:83–90.
- de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071–1076.
- Desmond DW: Cognition and white matter lesions. Cerebrovasc Dis 2002;13(suppl 2): 53–57.
- Longstreth WT Jr, Manolio TA, Arnold A, et al: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3,301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274–1282.
- Basile AM, Pantoni L, Pracucci G, et al: Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis 2006;21:315–322.
- Shenkin SD, Bastin ME, Macgillivray TJ, et al: Cognitive correlates of cerebral white matter lesions and water diffusion tensor parameters in community-dwelling older people. Cerebrovasc Dis 2005;20:310–318.
- Schmidt R, Scheltens P, Erkinjuntti T, et al: White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004;63:139–144.
- Gorter JW: Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319–1327.
- Mantyla R, Erkinjuntti T, Salonen O, et al: Variable agreement between visual rating scales for white matter hyperintensities on MRI. Comparison of 13 rating scales in a poststroke cohort. Stroke 1997;28:1614–1623.
- Kapeller P, Barber R, Vermeulen RJ, et al: Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke 2003;34:441–445.
- Prins ND, van Straaten EC, van Dijk EJ, et al: Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004;62:1533–1539.
- Anbeek P, Vincken KL, van Osch MJ, Bisschops RH, van der Grond J: Probabilistic segmentation of white matter lesions in MR imaging. Neuroimage 2004;21:1037–1044.
- Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J: Probabilistic segmentation of brain tissue in MR imaging. Neuroimage 2005;27:795–804.
- Manschot SM, Brands AM, van der Grond J, et al: Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006;55:1106–1113.
- Scheltens P, Barkhof F, Leys D, et al: A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7–12.
- Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P: Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187–198.
- Smith SM: Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143–155.
- Wardlaw JM, Ferguson KJ, Graham C: White matter hyperintensities and rating scales-observer reliability varies with lesion load. J Neurol 2004;251:584–590.
- van den Heuvel DM, ten Dam V, de Craen AJ, et al: Measuring longitudinal white matter changes: comparison of a visual rating scale with a volumetric measurement. AJNR Am J Neuroradiol 2006;27:875–878.
- van Straaten EC, Fazekas F, Rostrup E, et al: Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke 2006;37:836–840.
- DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ: Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005;36:50–55.
- Schmidt R, Schmidt H, Kapeller P, Lechner A, Fazekas F: Evolution of white matter lesions. Cerebrovasc Dis 2002;13(suppl 2):16–20.
- Barkhof F, Scheltens P: Is the whole brain periventricular? J Neurol Neurosurg Psychiatry 2006;77:143–144.
- Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F: Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046–2048.
- Van den Heuvel DM, ten Dam V, de Craen AJ, Admiraal-Behloul F, Olofsen H, Boilen FL, et al: Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry 2006;77:149–153.
- Prins ND, van Dijk EJ, den Heijer T, et al: Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005;128:2034–2041.
- Davis GK, Cohen RA, Paul RH, et al: Computer-mediated measurement and subjective ratings of white matter hyperintensities in vascular dementia: relationships to neuropsychological performance. Clin Neuropsychol 2004;18:50–62.
- Gouw AA, Van der Flier WM, van Straaten EC, et al: Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. J Neurol 2006;253:1189–1196.
- Sachdev P, Cathcart S, Shnier R, Wen W, Brodaty H: Reliability and validity of ratings of signal hyperintensities on MRI by visual inspection and computerised measurement. Psychiatry Res 1999;92:103–115.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.